Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | SHPH | COMMON STOCK | 280K | Aug 29, 2022 | Direct | F1 |
Id | Content |
---|---|
F1 | The undersigned became a Reporting Person subject to Section 16 reporting on August 29, 2022 at the time Shuttle Pharmaceuticals Holdings, Inc ("Company") completed its initial public offering ("IPO"). At the time of the Offering, the Reporting Person was the beneficial owner of 280,480 shares of common stock of the Company, consisting of (i) 138,889 shares of common stock and warrants to purchase 138,889 shares of common stock issuable upon conversion of Series A convertible preferred stock, which stock converts upon close of the Company's IPO, all of which are held by the William Henry Adkins & Pauline Adkins 1993 Revocable Trust, and (ii) 2,702 restricted stock units held by the Reporting Person, all of which have all fully vested as of the date of this report. |